It was also reported that treatment with a different Shh pathway agonist (Purmorphamine) administered at an early post-stroke stage (6 h) leads to decreased neuronal damage, BBB integrity and reduced reactive astrogliosis [102]. This evidence concerns the gene SHH and Stroke.